Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Gerard Flesch"'
L'optimisation du rapport entre l'efficacité du médicament et ses effets indésirables est indispensable pour une utilisation rationnelle.Les étapes essentielles de la recherche et du développement d'une molécule sont de déterminer la cible, le
Publikováno v:
British Journal of Clinical Pharmacology. 80:75-85
Aims This study characterized the population pharmacokinetics (PK) of imatinib in patients with severe pulmonary arterial hypertension (PAH), investigated drug–drug interactions (DDI) among imatinib, sildenafil and bosentan, and evaluated their cli
Publikováno v:
Drug Metabolism and Disposition. 39:1103-1110
Oxcarbazepine (OXC) is an antiepileptic drug. In humans, OXC is metabolized via reduction and conjugation. Monohydroxy derivative of OXC (MHD) is the major pharmacologically active component after OXC ingestion. This study was performed to characteri
Autor:
Gerard Flesch
Publikováno v:
Clinical Drug Investigation. 24:185-203
Oxcarbazepine (GP 47680, 10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine- 5-carboxamide) is an antiepileptic drug registered worldwide by Novartis under the trade name Trileptal((R)). Trileptal((R))is approved as adjunctive therapy or monotherapy for the
Publikováno v:
British journal of clinical pharmacology. 80(1)
This study characterized the population pharmacokinetics (PK) of imatinib in patients with severe pulmonary arterial hypertension (PAH), investigated drug-drug interactions (DDI) among imatinib, sildenafil and bosentan, and evaluated their clinical i
Autor:
Peter J. Wyld, Paul Rolan, Kelvin R. Palmer, Irving S. Benjamin, Peter M. Lloyd, F. Mullins, Felix Waldmeier, Gerard Flesch, Laurence J. Brookman, Antoine Sioufi
Publikováno v:
Clinical Pharmacology & Therapeutics. 62:272-278
Objectives Valsartan (CGP 48933), an orally active angiotensin II antagonist, is eliminated mainly by hepatic clearance. To characterize the compound(s) excreted in the bile, biliary excretion of valsartan was investigated by collection of bile after
Publikováno v:
Biopharmaceutics & Drug Disposition. 16:603-614
A study was performed in ten patients, stabilized with oxcarbazepine monotherapy (450–750 mg bid) for two weeks minimum, to investigate the possibility of using saliva to monitor the oxcarbazepine therapy. Thirteen paired blood and saliva samples w
Publikováno v:
Journal of chromatography. B, Biomedical sciences and applications. 696(1)
A liquid chromatographic assay for the determination of CGP 61755 (I) in plasma and urine is described. A similar method for CGP 53437, another HIV-1 protease inhibitor, has been developed and reported previously. After a deproteinization step, a liq
Autor:
Gunilla Steinwall, Per Sandstedt, Heimo L. Nilsson, Jan Arvidsson, Bernt Tonnby, Gerard Flesch
Publikováno v:
Journal of child neurology. 10(2)
A suppository for rectal administration of carbamazepine has been developed for situations in which it is unsuitable to use the oral route of administration. In an open, controlled, within-patient study, the pharmacokinetics, clinical efficacy, and t
Publikováno v:
Biopharmaceuticsdrug disposition. 15(6)
The effect of food on the pharmacokinetics of the antiepileptic oxcarbazepine (OXC) was investigated in healthy volunteers. Six healthy male volunteers were treated with single peroral doses of 600 mg of oxcarbazepine (Trileptal) after overnight fast